Pharmaceutical chemists have developed a novel method of generating highly specific antibodies to extracellular targets. By combining conventional phage display methods with their novel selection approach, the inventors have overcome previous limitations of antibody generation such as the selection and amplification of non-specific targets. Their methodology is technically simple and can be readily adopted by companies interested in developing antibodies for human therapeutics or preclinical model systems.
Current methods for generating antibodies against cell surface expressed antigens are inefficient and time-consuming, requiring the overproduction and/or purification of each extracellular target of interest. Although there has been considerable effort spent on optimizing in vitro phage display selection methods using large antibody libraries against these membrane-bound targets on whole cells, significant problems remain. The major limitation is to distinguish the antibodies generated from all proteins on the cell surface (background) from the protein of interest.
The inventors sought to develop a novel way to specifically select for phage bound only to the antigen of interest. This novel invention provides the following advantages:
• Generates high affinity antibodies.
• Generates highly specific antibodies.
• Enables production of therapeutically relevant antibodies.
• Technically simple approach.
• Robust and rapid approach.
To develop and commercialize this technology as an efficient method for selecting functional antibodies to extracellular targets.